DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insights 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the Spleen Tyrosine Kinase (SYK) Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spleen Tyrosine Kinase (SYK) Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Report

• DelveInsight’s Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Spleen Tyrosine Kinase (SYK) Inhibitors treatment.
• The leading companies working in the Spleen Tyrosine Kinase (SYK) Inhibitors Market include Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences, and others.
• Promising Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Therapies in the various stages of development include Cevidoplenib dimesylate, HMPL-523, and others.
• The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.
• An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.

 

Request a sample and discover the recent advances in Spleen Tyrosine Kinase (SYK) Inhibitors Treatment Drugs @ Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Report

 

In the Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spleen Tyrosine Kinase (SYK) Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Spleen Tyrosine Kinase (SYK) Inhibitors Overview

SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells. Mammals also express a SYK homologue, ZAP70, which is mostly restricted to T- and NK-lineage cells. SYK-related kinases are also found in invertebrates.

 

Find out more about Spleen Tyrosine Kinase (SYK) Inhibitors Therapeutics Assessment @ Spleen Tyrosine Kinase (SYK) Inhibitors Preclinical and Discovery Stage Products

 

Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs Profile

• Cevidoplenib dimesylate: Genosco
• HMPL-523: Hutchison MediPharma

 

Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Spleen Tyrosine Kinase (SYK) Inhibitors. The Spleen Tyrosine Kinase (SYK) Inhibitors companies which have their Spleen Tyrosine Kinase (SYK) Inhibitors drug candidates in the most advanced stage, i.e. phase II and Phase II/III include, Rigel Pharmaceuticals, TopiVert etc.

 

DelveInsight’s Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Molecule Type

 

Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Products have been categorized under various Molecule types such as

• Monoclonal antibodies
• Small molecules
• Product Type

 

Learn more about the emerging Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Therapies @ Spleen Tyrosine Kinase (SYK) Inhibitors Clinical Trials Assessment

 

Scope of the Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Report

• Coverage- Global
• Spleen Tyrosine Kinase (SYK) Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Spleen Tyrosine Kinase (SYK) Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Spleen Tyrosine Kinase (SYK) Inhibitors Companies- Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences, and others.
• Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Therapies- Cevidoplenib dimesylate, HMPL-523, and others.

 

Dive deep into rich insights for new drugs for Spleen Tyrosine Kinase (SYK) Inhibitors Treatment, Visit @ Spleen Tyrosine Kinase (SYK) Inhibitors Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spleen Tyrosine Kinase (SYK) Inhibitors – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
9. Late Stage Products (Phase II/III)
10. TOP 1630: TopiVert
11. Mid Stage Products (Phase II)
12. Cevidoplenib: Genosco
13. PRT 2761: Portola Pharmaceuticals
14. Early Stage Products (Phase I/II)
15. Gusacitinib: Asana BioSciences
16. Early Stage Products (Phase I)
17. Mivavotinib: Takeda Oncology
18. Pre-clinical and Discovery Stage Products
19. Research programme: small molecule therapeutics: Genosco
20. Inactive Products
21. Comparative Analysis
22. Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
23. Appendix

 

For further information on the Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline therapeutics, reach out to Spleen Tyrosine Kinase (SYK) Inhibitors Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market